Bringing the Oncology Community Together

BOLERO-2 Halted After Positive Interim Analysis

Marissa Murtaugh
Published Online: Wednesday, July 13, 2011
Afinitor (everolimus) tablet An interim analysis of a phase III study of Afinitor (everolimus) tablets combined with exemestane in women with breast cancer revealed that the regimen significantly extended progression-free survival (PFS) compared to placebo plus exemestane, which put an early end to the trial.

Known as BOLERO-2 (Breast cancer trials of OraL EveROlimus-2), this trial was a randomized, double-blind study involving more than 700 postmenopausal women from 195 sites worldwide. Each participant in the study had estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)­–negative metastatic breast cancer, whose disease had already progressed despite endocrine therapy with nonsteroidal aromatase inhibitors.  Patients who had received more than 1 regimen of chemotherapy for advanced breast cancer were not included in the study. Progression-free survival was the primary endpoint of this trial.

While enrolled in the study, patients were divided into 2 groups. One group received continuous therapy with oral everolimus 10 mg/day, while the second arm received placebo plus oral exemestane 25 mg/day. Twice as many patients were randomized to the everolimus group than the placebo group.

Everolimus works by targeting the mTOR protein in cancer cells that helps regulate tumor cell division and cell metabolism. The study sponsor, Novartis, did not specify in its statement the PFS rates in the 2 sets of patients, or provide data on the secondary endpoints of overall survival, overall response rate, incidence of adverse events, patient-reported outcomes, or the clinical benefit rate. Aside from this, Novartis did note that results from the study would be presented at a medical conference this year.

Related Articles
AR Findings Highlight Detailed Tumor-Profiling Study
A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression
Phase III Clinical Trials in HER2-Positive Breast Cancer
Expert panelists explore several large clinical trials examining therapies for patients with HER2-positive breast cancer that are currently ongoing or have recently completed.
Experts Support Broader Pertuzumab Use in HER2-Positive Breast Cancer
The recent approval of pertuzumab as part of a combination neoadjuvant treatment for patients with early-stage breast cancer has paved the way for wider use of the regimen in preoperative settings.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.